Optimi Health to Launch 200-Patient Phase 2 Psilocybin Trial for Major Depressive Disorder

summarizeSummary

Optimi Health announced a Health Canada-authorized Phase 2 trial of psilocybin-assisted therapy for major depressive disorder, enrolling up to 200 patients across Canada with dosing expected to complete by end of 2027.

check_boxKey Events · Product Development and Regulatory · OPTH

• Phase 2 MDD Trial Authorized

  Health Canada authorized a multisite Phase 2 trial evaluating a single supervised dose of natural psilocybin for major depressive disorder, with up to 200 participants across Canada.

• Largest Clinical Commitment to Date

  The 200-subject study is Optimi's largest clinical trial and among the largest studies of naturally derived psilocybin to date, with the company supplying its own GMP-manufactured psilocybin and retaining exclusive ownership of trial results.

• Timeline and Endpoint

  Trial initiation is planned for the first half of 2027, with dosing expected to be complete by the end of 2027. The primary efficacy endpoint is change in MADRS total score from baseline.

• Funding from Cash on Hand

  CEO Dane Stevens stated the trial can be comfortably funded with current cash on hand, following the company's Q3 FY2026 report of a $5.7M net loss and a 12-month cash runway.

auto_awesomeAnalysis · OPTH · Life Sciences

Optimi Health is moving from commercial supplier to clinical drug developer with a Health Canada-authorized Phase 2 trial in major depressive disorder. The 200-participant study is among the largest ever for naturally derived psilocybin and gives the company exclusive ownership of the data — a potential registration pathway. The CEO says current cash on hand covers the cost, which matters given the company's recent $5.7M quarterly loss and reliance on a $100M equity line. This is a meaningful strategic expansion, though the trial won't start until the first half of 2027 and topline results are years away.